Sign in to view content

Assessment of Central Subfield Thickness Fluctuations and Impact on Vision in Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS)

Chirag D. Jhaveri, MD, FASRS

Video
Published 2021

Related

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials
Dilsher S. Dhoot, MD
On Demand Cases, Courses, and Papers
2021
The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections
Kapil Mishra, MD
On Demand Cases, Courses, and Papers
2021
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial
Maziar Lalezary, MD
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more